Ondansetron Eg

Ondansetron, the active ingredient in Ondansetron Eg, is a 5-HT3 receptor antagonist presented as a 4 mg tablet for oral use. It helps prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetron Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to manage nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: helps control symptoms during and after radiotherapy. - Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures. - Pregnancy‑related nausea (hyperemesis gravidarum): provides relief when other therapies are insufficient.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement difficulty. - Diarrhoea: loose stools, usually transient. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: light‑headed sensation. - Injection site pain (if administered intravenously).

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation that may lead to irregular heart rhythm. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: rare condition with agitation, tremor, and hyperreflexia. - Hepatic dysfunction: elevated liver enzymes indicating liver stress. - Vision changes: blurred vision or visual disturbances. - Persistent vomiting despite therapy: may indicate underlying condition progression.

When using Ondansetron, consider the following precautions: - Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be observed. - Electrolyte assessment: correct potassium, magnesium, or calcium abnormalities before therapy. - Drug interactions: review concomitant medications that may affect cardiac rhythm. - Pregnancy and lactation: use only if clearly needed; discuss risks with a healthcare professional. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgment. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ondansetron can interact with several medicines that influence cardiac rhythm or serotonin pathways.

Major Interactions (Avoid): - Anti‑arrhythmic agents (e.g., amiodarone, quinidine): may increase QT prolongation risk. - Certain antipsychotics (e.g., haloperidol, ziprasidone): additive effect on QT interval. - Serotonergic drugs (e.g., tramadol, linezolide): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP2D6 substrates (e.g., metoprolol, codeine): potential alteration of their metabolism. - Oral contraceptives: may experience reduced efficacy. - Antacids containing aluminum or magnesium: can lower oral absorption. - Diuretics: electrolyte shifts may augment QT‑related risk.